SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: sam who wrote (3182)12/7/1997 7:16:00 AM
From: Andreas Helke  Read Replies (2) of 6136
 
I think it this is pretty much business as usual. The chemical departments of the pharmas have huge libraries of compounds wich might be useful as medicaments. The difficult part is then to figure out wich of these compounds to use for what indication. When Agouron searched a PI inhibitor they then screened the Eli Lilly library and since they found a suitable candidate it was of course a compound that was invented by Eli Lillys chemists. It was then just luck for Agouron that Eli Lilly later lost interest in the collaboration.

Andreas
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News